Rheumatoid arthritis is still expensive in the new decade: a comparison between two early RA cohorts, diagnosed 1996–98 and 2006–09

Hallert, Eva; Husberg, Magnus; Kalkan, Almina; Bernfort, Lars

doi:10.3109/03009742.2015.1126344

Cited by 14 publications

(20 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Costs incurred from visits to other healthcare professionals, such as nurse, physical therapist, and occupational therapist, that were measured separately in some studies, 15,17,18,20,21,27,29,31,37,[47][48][49][50][51][52][53][54][55] were summarized as "Outpatient". Costs for diagnostic tests, devices and adaptation, transportation and informal care were categorised as "Others".…”

Section: Resultsmentioning

confidence: 99%

“…The studies that adopted the incidence-based approach, focused on recent-onset patients and were primarily conducted in a European setting. [14][15][16][17][18][19][20][21] Cost components and measurement of direct or indirect costs also varied markedly due to the aims and data availability among studies. Twenty-seven studies reported both direct and indirect costs, while 36 studies and 9 studies reported direct and indirect costs only, respectively.…”

Section: Methodological Approachesmentioning

confidence: 99%

“…For studies where indirect costs dominated, the approach to estimating indirect costs had an important impact. It was observed that work disability measured by disability pension was taken into account in these studies [16][17][18]30,31 , except for two studies from Mexico and Hong Kong 32,33 , where indirect costs were driven by unemployment due to RA. On the other hand, for those studies where direct costs dominated, work disability was generally not included as an indirect cost component 28,[34][35][36][37][38] .…”

Section: Direct and Indirect Costs Of Ramentioning

confidence: 99%

See 2 more Smart Citations

Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era

Hsieh

Geue

et al. 2020

Annals of the Rheumatic Diseases

138

View full text Add to dashboard Cite

BackgroundThe past decades have seen rapid advances in the treatment of rheumatoid arthritis (RA). In particular, the introduction of biologic and targeted synthetic disease-modifying antirheumatic drugs have improved clinical outcomes and reconfigured traditional RA cost compositions.ObjectivesTo map the existing evidence concerning cost of illness of RA, as the treatment pathway evolves in the biologic era, and examine how costs have been measured and estimated, in order to assemble and appropriately interpret available data.MethodsSystematic review of studies that estimated the costs of patients with RA. Multiple electronic databases were searched to identify studies published between 2000 and 2019. The reported total costs and cost components were evaluated according to the study and population characteristics. The Cochran-Armitage test was used to determine statistically significant trends in increasing or decreasing proportions over time.ResultsOverall, 72 studies were included. Drug costs compromised the main component (up to 87%) of direct costs with an increasing trajectory over time, although not statistically significant. The proportion of costs for hospitalisation showed a statistically significant decrease chronologically (p=0.044). Indirect costs, primarily associated with absenteeism and work disability accounted for 39% to 86% of total costs. The reported indirect costs are highly sensitive to the approach to estimation.ConclusionsA decreasing trend in inpatient costs chronologically suggested a cost shift in other components of direct costs. Indirect costs still contributed a considerable proportion of total costs, with work disability being the main cost component. Economic analyses that do not incorporate or appropriately measure indirect costs will underestimate the full economic impact of RA.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Methodological Approachesmentioning

confidence: 99%

Section: Direct and Indirect Costs Of Ramentioning

confidence: 99%

See 1 more Smart Citation

Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era

Hsieh

Geue

et al. 2020

Annals of the Rheumatic Diseases

138

View full text Add to dashboard Cite

show abstract

“…Despite strongly reduced levels of disease activity with biological DMARD treatment, many patients report being on sick leave for extended periods, and work disability is still a major problem (14). In comparison with studies on biological drugs, relatively few studies have measured the effect of conventional DMARD therapy on sick leave in RA patients (15)(16)(17)(18)(19)(20). These studies mainly show a decrease in days on sick leave due to treatment, but also an increase in the number of patients without a paid job, and patients with a disability pension as well as those on retirement.…”

mentioning

confidence: 99%

Predictors of sick leave and improved worker productivity after 52 weeks of intensive treatment in patients with early rheumatoid arthritis

Blomjous

Boers

Uyl

et al. 2019

Scandinavian Journal of Rheumatology

View full text Add to dashboard Cite

Objective: To identify predictors of sick leave and improved worker productivity in patients with early rheumatoid arthritis (RA) treated for 52 weeks with intensive combination strategies. Methods: Patients with early RA were included in the COmbinatietherapie Bij Reumatoïde Artritis (COBRA)-light trial and followed for 52 weeks. As the COBRA-light strategy proved to be non-inferior to the COBRA strategy, all patients were pooled. Predictors for sick leave and improved worker productivity were assessed through a 3 month time-lag multivariable logistic generalized estimating equations model. Results: At baseline, 97 patients had a paid job, 59 had no job, and for six patients the work status was unknown. During the trial, 13 patients stopped working (8%) and six started working (4%). Only sick leave in the past 3 months predicted sick leave. By excluding this variable, patient global assessment and actual hours of sick leave became predictors. Increased worker productivity was predicted by higher patient global assessment levels, Sharp van der Heijde score ≥ 1, actual hours on sick leave, and higher worker productivity in the past 3 months. Conclusion: Sick leave and improved worker productivity were mainly predicted by non-disease-specific variables. Both outcomes can be predicted on a 3 month basis, using the outcome over the past 3 months for the next 3 months. By applying this model in daily practice, decisions for therapy change could be based not solely on disease activity but also taking into account a possible high risk for sick leave in the upcoming 3 months.

show abstract

“…A new cohort (T2) was established 2006-2009 and followed similarly. During year one, both cohorts improved, but T2 to a larger extent (4). Given the paradigm shift in RA-treatment, comprising not only biological drugs, but also early, aggressive treatment with traditional DMARDs in double and triple combinations, our intention was to calculate costs and evaluate consequences in real life over two years, for patients included during two periods with different treatment regimes.…”

mentioning

confidence: 99%

Costs and disease activity in early rheumatoid arthritis in 1996–2000 and 2006–2011, improved outcome and shift in distribution of costs: a two-year follow-up

Husberg

Bernfort

Hallert

2018

Scandinavian Journal of Rheumatology

Self Cite

View full text Add to dashboard Cite

show abstract

Rheumatoid arthritis is still expensive in the new decade: a comparison between two early RA cohorts, diagnosed 1996–98 and 2006–09

Cited by 14 publications

References 31 publications

Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era

Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era

Predictors of sick leave and improved worker productivity after 52 weeks of intensive treatment in patients with early rheumatoid arthritis

Costs and disease activity in early rheumatoid arthritis in 1996–2000 and 2006–2011, improved outcome and shift in distribution of costs: a two-year follow-up

Contact Info

Product

Resources

About